id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-E-0299-0008,FDA,FDA-2014-E-0299,Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2016-12-28T05:00:00Z,2016,12,2016-12-28T05:00:00Z,,2016-12-28T15:52:28Z,,0,0,090000648243b09e
FDA-2014-E-0299-0007,FDA,FDA-2014-E-0299,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-12-01T05:00:00Z,2015,12,2015-12-01T05:00:00Z,,2015-12-01T17:35:00Z,,0,0,0900006481d7da9e
FDA-2014-E-0299-0006,FDA,FDA-2014-E-0299,"Determination of Regulatory Review Period for Purposes of Patent
Extension; KYNAMRO",Notice,Determinations,2015-04-24T04:00:00Z,2015,4,2015-04-24T04:00:00Z,2015-10-22T03:59:59Z,2015-04-24T13:29:13Z,2015-09522,0,0,0900006481ab809b
FDA-2014-E-0299-0005,FDA,FDA-2014-E-0299,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-03-31T04:00:00Z,2015,3,2015-03-31T04:00:00Z,,2015-03-31T18:35:25Z,,0,0,0900006481a7eb06
FDA-2014-E-0299-0004,FDA,FDA-2014-E-0299,Letter from U.S. Patent and Trademark Office to FDA,Other,Letter(s),2015-02-27T05:00:00Z,2015,2,2015-02-27T05:00:00Z,,2015-02-27T14:12:06Z,,0,0,0900006481a1b5e1
FDA-2014-E-0299-0003,FDA,FDA-2014-E-0299,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2014-03-27T04:00:00Z,2014,3,2014-03-27T04:00:00Z,,2014-03-27T16:35:57Z,,0,0,0900006481687480
FDA-2014-E-0299-0001,FDA,FDA-2014-E-0299,Patent Extension from Genzyme Corporation,Other,Application,2014-03-13T04:00:00Z,2014,3,2014-03-13T04:00:00Z,,2014-03-13T13:22:48Z,,0,0,090000648166239f
FDA-2014-E-0299-0002,FDA,FDA-2014-E-0299,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2014-03-13T04:00:00Z,2014,3,2014-03-13T04:00:00Z,,2014-03-13T13:23:18Z,,0,0,090000648166239d